Cadrenal Therapeutics’ (CVKD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Cadrenal Therapeutics (NASDAQ:CVKDFree Report) in a research note released on Thursday, Benzinga reports. They currently have a $3.00 target price on the stock.

Cadrenal Therapeutics Stock Down 1.9 %

Shares of NASDAQ CVKD opened at $0.50 on Thursday. Cadrenal Therapeutics has a twelve month low of $0.36 and a twelve month high of $3.14. The business has a fifty day simple moving average of $0.46 and a two-hundred day simple moving average of $0.64. The firm has a market cap of $8.00 million, a PE ratio of -1.61 and a beta of 1.70.

Cadrenal Therapeutics (NASDAQ:CVKDGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). On average, research analysts expect that Cadrenal Therapeutics will post -0.34 earnings per share for the current year.

Institutional Trading of Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKDFree Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 982,285 shares of the company’s stock, valued at approximately $668,000. Armistice Capital LLC owned about 7.54% of Cadrenal Therapeutics at the end of the most recent reporting period. 7.92% of the stock is owned by institutional investors and hedge funds.

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.

Recommended Stories

Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with's FREE daily email newsletter.